Fig. 3: GLUD2 mutation decreases glutamate transporter expression in MPTP-treated mice.
From: Functional validation of a human GLUD2 variant in a murine model of Parkinson’s disease
a Expression levels of NR2A, GluA1, GluA2, EAAT1, and EAAT2 in the SN of AAV-GFP, MPTP + AAV-GFP, MPTP + AAV-GLUD2, and MPTP + AAV-GLUD2 T1492G groups of mice were determined by western blotting. n = 6. b, c Immunofluorescent staining of GFP, GFAP, and EAAT1 or EAAT2 in the SNpc of AAV-GFP, MPTP + AAV-GFP, MPTP + AAV-GLUD2, and MPTP + AAV-GLUD2 T1492G groups (scale bars: upper, 40 µm; lower, 8 µm). d Effect of GLUD2 or its mutant on the expression of GDH2, GDH1, GFAP, EAAT1 and EAAT2 in MPP+-treated U251 cells was determined by western blotting. The bottom band (~55 KD) in the GDH2 blot is non-specific. n = 3. Results are expressed as the mean ± SEM. **p < 0.01, *p < 0.05 vs. AAV-GFP group or untreated U251 cells. ##p < 0.01 vs. MPTP + AAV-GFP or MPP+ group. &&p < 0.01, &p < 0.05 vs. MPP+ + GLUD2 group. Statistical significance was determined by one-way ANOVAs and Tukey tests for post-hoc comparisons.
